Live

Stocks are rallying as Trump eased fears over China tariffs and Powell. See the latest.

NasdaqCM - Delayed Quote USD

Aspire Biopharma Holdings, Inc. (ASBPW)

0.0600

+0.0100

+(20.00%)

As of April 22 at 4:00:00 PM EDT. Market Open.

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 7 days ago

BNZI

BNZIW

SEVCF
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, ...

ACCESS Newswire 9 days ago

ASBP
-0.23%
ASBPW
+20.00%
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Plans to conduct consumer and safety testing during second quarter 2025 Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial production Single dose pre-workout supplement expected to be available ...

ACCESS Newswire 12 days ago

ASBP
-0.23%
ASBPW
+20.00%
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

One clinical trial site activated Patient enrollment expected in April Trial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin product Aspire anticipates releasing initial clinical data from trial at ...

ACCESS Newswire 14 days ago

ASBP
-0.23%
ASBPW
+20.00%
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submission Company expects to commence bioavailability study in April 2025 Aspire intends to request "fast track" approval on FDA ...

ACCESS Newswire last month

ASBP
-0.23%
ASBPW
+20.00%
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today provided an update ...

ACCESS Newswire last month

ASBP
-0.23%
ASBPW
+20.00%
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

SmallCaps Daily Dives Deep with CEO Kraig Higginson to Discuss Aspire's Mission to Enhance Efficacy and Reduce Side Effects New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company") is revolutionizing drug delivery through its proprietary sublingual technology, designed to rapidly deliver therapeutics while bypassing the gastrointestinal tract and liver. SmallCaps Daily sat down with CEO Kraig Higginson to learn more about

Newsfile last month

ASBP
-0.23%
ASBPW
+20.00%
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

New product expected to set a new standard for potency and performance in the estimated $20 billon pre-workout market Desert Stream Inc., a well-established nutritional and supplement manufacturer of caffeine-based products, engaged for sourcing of ...

ACCESS Newswire last month

ASBP
-0.23%
ASBPW
+20.00%
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete Test results support the next development step with Phase 1clinical trial expected to commence in April Provides Summary of Expected ...

ACCESS Newswire last month

ASBP
-0.23%
ASBPW
+20.00%
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Aspire Biopharma, Inc. ("Aspire" or the "Company"), a developer of a multi-faceted patent-protected disruptive drug delivery mechanism technology (Nasdaq:ASBP)(Nasdaq:ASBPW), today announced ...

ACCESS Newswire last month

ASBP
-0.23%
ASBPW
+20.00%